Document Detail


Non-metastatic Ewing's sarcoma: twenty years of experience suggests that surgery is a prime factor for successful multimodality therapy.
MedLine Citation:
PMID:  10339654     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Eighty-five patients (37 female, 48 male; median age 14 years) with non-metastatic Ewing's sarcoma received definitive treatment at the University of Texas M.D. Anderson Cancer Center between 1969 and 1988. Multidisciplinary therapy was administered as follows: combination chemotherapy (CC) and local radiotherapy (XRT): 65 patients; CC, XRT and surgery, 19 patients; and XRT and surgery, 1 patient. This permitted a 10-20 year follow-up for 75% of our patients. The overall survival at 5 and 10-20 years was 46.1%, and 37.2%, respectively. At 5 years, 80.5% of live patients had control of local disease. The influence of sex, age, ethnicity, primary site, size, lactic dehydrogenase (LDH) level, presence or absence of systemic symptoms, and XRT dose (<60 Gy and </=60 Gy) was analyzed and was not found to be of prognostic significance in survival. The presence of a soft tissue mass at diagnosis was found to be a significant unfavorable prognostic variable. Nine of 11 patient who underwent resection after CC and/or XRT had residual tumor in the surgical specimen. Patients who received surgery as part of the planned treatment of their primary tumor had significantly better local control and disease-free survival than those who did not undergo resection. Complications in long-term survivors are described.
Authors:
S S Givens; S Y Woo; L Y Huang; T A Rich; M H Maor; A Cangir; J A Murray; M J Oswald; L J Peters; N Jaffe
Related Documents :
17075094 - Does the method of treatment affect the outcome in soft-tissue sarcomas of the adductor...
17072434 - Synovial sarcoma of the extremities: prognostic factors for 20 nonmetastatic cases and ...
22863724 - Long-term survival in patients with metastatic breast cancer receiving intensified chem...
22833464 - Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (pe...
21607554 - Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatmen...
25059344 - Clinicopathological factors predicting r0 resection and long-term survival after esopha...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  International journal of oncology     Volume:  14     ISSN:  1019-6439     ISO Abbreviation:  Int. J. Oncol.     Publication Date:  1999 Jun 
Date Detail:
Created Date:  1999-06-29     Completed Date:  1999-06-29     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  9306042     Medline TA:  Int J Oncol     Country:  GREECE    
Other Details:
Languages:  eng     Pagination:  1039-43     Citation Subset:  IM    
Affiliation:
Department of Clinical Radiotherapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Bone Neoplasms / drug therapy,  radiotherapy,  secondary,  surgery*
Child
Child, Preschool
Combined Modality Therapy
Disease-Free Survival
Female
Follow-Up Studies
Humans
Male
Prognosis
Retrospective Studies
Sarcoma, Ewing's / drug therapy,  radiotherapy,  secondary,  surgery*
Grant Support
ID/Acronym/Agency:
CA06294/CA/NCI NIH HHS

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prognostic value of plasma HER-2/neu in African American and Hispanic women with breast cancer.
Next Document:  Protein synthesis inhibitor-mediated stability of adenomatous polyposis coli mRNA levels in HCT-116 ...